KCNA5 Antibody

What is KCNA5 and why is it important in research?

KCNA5 (Potassium Voltage-Gated Channel Subfamily A Member 5), also known as Kv1.5, is a shaker-related voltage-gated potassium channel encoded by the KCNA5 gene in humans. It consists of six membrane-spanning domains with a shaker-type repeat in the fourth segment and belongs to the delayed rectifier class. Its primary function includes restoring the resting membrane potential of neurons and cardiac muscle cells after depolarization .

The channel is expressed in:

• Cardiac and smooth muscle tissue (colon, aorta, stomach, pulmonary artery)

• Neurons

• Kidney

• Pulmonary vasculature

KCNA5 has significant research importance because:

• Mutations in the gene encoding the channel have been found in atrial fibrillation patients

• It plays a role as a cardiac action potential regulator

• It has been implicated in idiopathic pulmonary arterial hypertension

• Recent studies suggest its involvement in cancer cell survival, particularly in breast cancer

What types of KCNA5 antibodies are available for research applications?

KCNA5 antibodies are available in various formats to accommodate different experimental needs:

The choice of antibody depends on the specific research question, experimental design, and target accessibility in your experimental system .

How should I validate a KCNA5 antibody for my specific application?

Thorough validation is crucial for ensuring reliable results with KCNA5 antibodies:

• Positive and negative controls:

  • Positive controls: Use tissues/cells known to express KCNA5 (brain, heart, pulmonary arteries)

  • Negative controls: Use KCNA5 knockout cells or tissues, or perform peptide competition assays with the immunizing peptide

• Multiple detection methods:

  • Cross-validate findings using two different antibodies targeting different epitopes

  • Confirm protein expression with mRNA detection (RT-PCR or RNA-Seq)

• Technical validation:

  • For Western blot: Verify that the observed band is at the expected molecular weight (~67-70 kDa)

  • For IHC/IF: Include antibody omission controls and isotype controls

  • For flow cytometry: Use isotype-matched control antibodies

• Blocking peptide experiments:

  • Pre-incubate the antibody with the immunizing peptide before application

  • Signal should be significantly reduced or eliminated

• Dilution optimization:

  • Test multiple dilutions to determine optimal signal-to-noise ratio

  • Common starting dilutions: WB (1:500-1:3000), IHC (1:100-1:2000), IF (1:100)

What are the optimal protocols for detecting KCNA5 in Western blots?

For optimal Western blot results with KCNA5 antibodies:

• Sample preparation:

  • For membrane proteins like KCNA5, avoid boiling samples as this can cause aggregation

  • Use mild detergents (0.1-1% Triton X-100 or NP-40) for extraction

  • Include protease inhibitors to prevent degradation

• Gel electrophoresis:

  • Use 8-10% polyacrylamide gels for optimal separation

  • Load appropriate positive controls (rat brain membranes work well)

• Transfer conditions:

  • Use PVDF membranes rather than nitrocellulose for better protein retention

  • Transfer at lower voltage (30V) overnight at 4°C for better transfer of membrane proteins

• Blocking and antibody incubation:

  • Block with 5% non-fat milk or BSA in TBST

  • Optimal dilution range: 1:500-1:3000 depending on the specific antibody

  • Incubate primary antibody overnight at 4°C for better results

• Detection considerations:

  • KCNA5 typically appears as a band at approximately 67-70 kDa

  • Additional bands may represent glycosylated forms or degradation products

  • For low abundance expression, consider using chemiluminescent substrates with extended exposure times

What are the best approaches for immunolocalization of KCNA5 in tissue and cell samples?

For successful immunolocalization of KCNA5:

• Fixation methods:

  • For tissues: 4% paraformaldehyde is recommended to preserve epitope accessibility

  • For cells: 2-4% paraformaldehyde for 10-15 minutes or methanol fixation for 5 minutes at -20°C

• Antigen retrieval (for FFPE tissues):

  • Heat-induced epitope retrieval using citrate buffer (pH 6.0) or Tris-EDTA (pH 9.0)

  • Optimize retrieval time (typically 10-20 minutes)

• Working dilutions:

  • IHC: 1:100-1:2000

  • IF: 1:100-1:500

  • ICC: 1:100

• Signal enhancement strategies:

  • For tissues with low expression: Consider using tyramide signal amplification (TSA)

  • For IF: Use of high quantum yield fluorophores (Alexa Fluor 488, 555, or 647)

• Co-localization studies:

  • KCNA5 has been successfully co-localized with:

    • Caveolin-1 in breast cancer cells

    • GABA in Purkinje cells using anti-parvalbumin antibodies

• Live cell detection:

  • For flow cytometry or live imaging, use antibodies targeting extracellular epitopes

  • Anti-KCNA5 extracellular antibodies have been successfully used at 2.5-5μg per sample for flow cytometry

Why might I observe inconsistent KCNA5 detection in my experimental system?

Several factors can contribute to inconsistent KCNA5 detection:

• Protein degradation:

  • KCNA5 is susceptible to proteolysis during sample preparation

  • Solution: Add protease inhibitor cocktail and maintain samples at 4°C throughout processing

• Epitope masking:

  • Post-translational modifications may block antibody binding sites

  • Solution: Try antibodies targeting different epitopes or consider phosphatase treatment if phosphorylation is suspected

• Expression variation:

  • KCNA5 expression can vary with cell cycle, stress conditions, or cell density

  • Solution: Standardize cell culture conditions and harvesting protocols

• Glycosylation state:

  • Mutations in KCNA5 can affect glycosylation, altering apparent molecular weight

  • Research shows mutant channels may be present in immature form while wild-type channels show mature glycosylated forms

• Detergent sensitivity:

  • As a membrane protein, KCNA5 extraction efficiency depends on detergent choice

  • Solution: Compare multiple detergents (Triton X-100, CHAPS, digitonin) to optimize extraction

• Antibody batch variation:

  • Different lots may have varying affinities and specificities

  • Solution: Validate each new lot against a previously successful lot

How can I distinguish between non-specific binding and true KCNA5 signal?

Distinguishing specific from non-specific signals requires systematic controls:

• Peptide competition assay:

  • Pre-incubate antibody with blocking peptide specific to the immunization epitope

  • True KCNA5 signals should be significantly reduced or eliminated

• Multiple antibody validation:

  • Use antibodies raised against different epitopes of KCNA5

  • True signals should be detected by multiple antibodies

• Genetic approaches:

  • siRNA knockdown of KCNA5 should reduce or eliminate specific signals

  • Overexpression systems can confirm antibody specificity

• Tissue/cell type specificity:

  • Compare signals in tissues/cells known to express KCNA5 (e.g., brain, heart) versus those with minimal expression

  • Pattern of expression should align with known distribution

• Signal characteristics:

  • For WB: KCNA5 typically shows a single band at 67-70 kDa

  • For IHC/IF: Membrane localization is expected, with some cytoplasmic staining during protein synthesis and trafficking

How can KCNA5 antibodies be used to study channel mutations and their functional consequences?

KCNA5 antibodies can be powerful tools for investigating channel mutations:

• Expression analysis of mutant channels:

  • Western blot analysis can reveal differences in expression levels between wild-type and mutant channels

  • Research has shown that mutations in the tetramerization (T1) domain (G182R and E211D) of KCNA5 affect protein expression levels

• Trafficking studies:

  • Immunolocalization can reveal differences in subcellular distribution

  • Some mutations affect trafficking from the ER to the plasma membrane, detectable by comparing membrane versus intracellular staining

• Post-translational modification analysis:

  • Glycosylation state can be assessed using glycosidase treatments followed by Western blot

  • Mutant channels may show altered glycosylation patterns, appearing in immature forms compared to wild-type channels

• Heterologous expression systems:

  • When expressed in HEK-293 cells, different KCNA5 mutations show distinct expression patterns and functional properties

  • Antibodies can help correlate electrophysiological data with protein expression levels

• Structure-function relationship studies:

  • Co-immunoprecipitation with channel interacting partners can reveal how mutations affect protein-protein interactions

  • Channel assembly can be studied using non-reducing versus reducing conditions in Western blots

What is the relationship between KCNA5 and caveolin-1, and how can this be studied using antibodies?

Recent research has revealed an important relationship between KCNA5 and caveolin-1 that can be investigated using antibody-based techniques:

• Co-expression analysis:

  • Dual immunofluorescence staining shows co-localization of KCNA5 and caveolin-1 in:

    • Breast cancer tissues

    • MCF-10A-neoT non-tumorigenic epithelial cells

    • MCF-7 human breast cancer cells

    • MDA-MB-231 breast cancer cells

• Functional coupling:

  • Studies show that caveolin-1 knockdown leads to decreased KCNA5 expression in multiple cell lines

  • Methyl-β-cyclodextrin treatment, which disrupts caveolae, reduces both caveolin-1 and KCNA5 expression in cell membranes

• Methodological approaches:

  • Co-immunoprecipitation to detect physical interaction

  • Proximity ligation assay to visualize close association in situ

  • Membrane fractionation followed by Western blot to assess distribution in lipid rafts

• Signaling pathway analysis:

  • KCNA5 knockdown decreases phosphorylated-AKT levels

  • Combined caveolin-1 and KCNA5 overexpression promotes cancer cell survival

  • Antibodies against phospho-AKT can be used alongside KCNA5 antibodies to study this relationship

• Experimental system recommendations:

  • MCF-10A-neoT cells: Express high levels of both proteins, good for knockdown studies

  • MCF-7 cells: Express low levels, ideal for overexpression studies

  • MDA-MB-231 cells: Higher expression than MCF-7, useful for comparative studies

How can flow cytometry with KCNA5 antibodies be optimized for live cell studies?

Flow cytometry with KCNA5 antibodies can provide valuable insights into channel expression on the cell surface of living cells:

• Antibody selection criteria:

  • Must target extracellular epitopes of KCNA5

  • Antibodies against the first extracellular loop (amino acids 268-279) have shown good results

  • Both direct (conjugated) and indirect detection methods can be used

• Optimization parameters:

  • Titration of antibody concentration (typically 2.5-5μg per sample)

  • Cell density (1-5 × 10^6 cells/mL recommended)

  • Incubation conditions (30-45 minutes at 4°C to prevent internalization)

  • Careful washing to remove unbound antibody without disrupting cell integrity

• Controls for rigorous analysis:

  • Isotype controls: Use matching IgG isotype-FITC for direct detection

  • Blocking controls: Pre-incubation with non-conjugated antibody

  • Positive controls: Cell lines with known KCNA5 expression (e.g., J774 macrophages, THP-1 monocytic leukemia cells)

• Data analysis considerations:

  • Gating strategy should exclude dead cells and debris

  • Mean fluorescence intensity (MFI) provides quantitative measure of expression level

  • Consider multiparameter analysis to correlate KCNA5 expression with cell cycle or activation status

• Applications in research:

  • Monitoring changes in channel expression during differentiation

  • Assessing effects of pharmacological agents on surface expression

  • Sorting based on KCNA5 expression levels for downstream functional studies

How are KCNA5 antibodies being used to investigate the role of this channel in cancer?

KCNA5 antibodies are becoming important tools in cancer research:

• Expression profiling:

  • IHC studies have revealed differential expression of KCNA5 in various cancer types

  • In breast cancer tissues, KCNA5 co-expression with caveolin-1 has been observed

• Mechanistic investigations:

  • Antibody-based studies have shown that:

    • KCNA5 expression correlates with AKT phosphorylation in breast cancer cells

    • KCNA5 knockdown decreases phosphorylated-AKT levels

    • KCNA5 and caveolin-1 co-expression promotes cancer cell survival

• Research methodologies:

  • Immunoblotting to quantify expression in different cancer cell lines

  • Immunofluorescence to determine subcellular localization

  • Flow cytometry to assess surface expression in cancer stem cells

• Therapeutic potential assessment:

  • Antibodies can be used to evaluate KCNA5 as a potential therapeutic target

  • Expression levels can be correlated with response to potassium channel modulators

  • Combined analysis of KCNA5 with signaling pathway components helps elucidate mechanism of action

• Future directions:

  • Development of function-blocking antibodies targeting extracellular domains

  • Creation of antibody-drug conjugates for targeted therapy

  • Use of antibodies to identify patient subgroups who might benefit from KCNA5-targeted interventions

What are the technical challenges in developing antibodies against specific conformational states of KCNA5?

Developing conformation-specific antibodies for KCNA5 presents unique challenges:

• Structural considerations:

  • KCNA5 undergoes significant conformational changes between open and closed states

  • The voltage sensor domain (S4) moves during activation

  • Specific epitopes may be accessible only in certain conformational states

• Immunization strategies:

  • Use of peptides that mimic specific conformational states

  • Immunization with full-length protein stabilized in specific conformations using toxins or mutations

  • Phage display selection under conditions that favor specific channel states

• Validation approaches:

  • Electrophysiological recordings combined with antibody application

  • Testing antibody binding under conditions that favor different channel states (voltage, pH, ionic composition)

  • Comparison of binding to wild-type versus mutation-stabilized conformations

• Applications in research:

  • Tracking conformational changes in real-time

  • Studying effects of disease-causing mutations on channel conformation

  • Investigating drug binding sites and mechanisms

• Methodological improvements:

  • Development of single-chain antibodies with better access to confined spaces

  • Use of nanobodies derived from camelid antibodies

  • Combination with emerging structural biology techniques (cryo-EM, mass photometry)

How can antibodies help explore the interaction between KCNA5 and other proteins in signaling complexes?

KCNA5 participates in macromolecular signaling complexes, and antibodies can help map these interactions:

• Co-immunoprecipitation strategies:

  • Antibodies against KCNA5 C-terminus are effective for pulling down channel complexes

  • Sequential immunoprecipitation can identify higher-order complexes

  • Crosslinking prior to immunoprecipitation can capture transient interactions

• Proximity-based methods:

  • Proximity ligation assay (PLA) visualizes protein interactions in situ

  • FRET-based approaches using antibodies conjugated to donor/acceptor fluorophores

  • BioID or APEX2 approaches combined with antibody validation

• Known interacting partners:

  • Caveolin-1: Forms functional coupling with KCNA5 in lipid rafts

  • XIRP2 (Xin Actin Binding Repeat Containing Protein 2): Interaction required for normal electrical conduction

  • Kvβ subunits: Regulate subcellular location and promote rapid inactivation

• Functional consequences of interactions:

  • Channel kinetics alterations (activation, inactivation)

  • Trafficking and membrane targeting

  • Signaling pathway activation (e.g., AKT pathway)

• Disease relevance:

  • Disruption of protein-protein interactions may underlie channelopathies

  • Therapeutic potential in targeting specific interactions rather than channel function

  • Antibodies can help identify which interactions are altered in disease states